CuraTeQ Biologics, a wholly owned step-down subsidiary of Aurobindo Pharma, has obtained marketing authorisation from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for Dazublys, its trastuzumab biosimilar version indicated for the treatment of HER2-positive breast and gastric cancers.

Earlier in July 2025, Dazublys received the marketing authorisation in the European Union from the European Commission (EC).

This is CuraTeQ’s fourth biosimilar to be approved by MHRA after the approval of Bevqolva in December 2024 and Zefylti in May 2025, and Dyrupeg in June 2025. Dazublys, Zefylti, and Dyrupeg are also approved in the European Union.        

The approval of Dazublys reinforces Aurobindo Pharma’s strategic focus on expanding its biosimilars portfolio, particularly in the oncology and immunology segments, with a goal of launching at least 10 biosimilars by 2030.

Headquartered in Hyderabad, CuraTeQ Biologics is focused on developing biosimilars for the treatment of various cancers and autoimmune diseases.

Its biosimilars manufacturing centre in Hyderabad is an EU GMP-certified, fully integrated commercial-scale facility. It has end-to-end capabilities in producing a full range of products from bulk drug substance (DS) to fill-finish and packaged drug products (DP).

CuraTeQ’s pipeline consists of 14 biosimilars, primarily targeting the immunology and oncology segments.